Triple Incretin Comparator Kit

Retatrutide is a triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon (GCGR) receptors. GLP-1 and GIP agonism drive insulin secretion and appetite suppression, while glucagon receptor activation increases energy expenditure and hepatic lipid oxidation. This triple mechanism addresses multiple metabolic pathways for potentially superior metabolic research and metabolic improvement over dual agonists.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that activates both incretin pathways simultaneously. It stimulates insulin secretion, suppresses glucagon in a glucose-dependent manner, and reduces appetite via central and peripheral signaling. The dual receptor engagement provides synergistic metabolic effects beyond GLP-1 agonism alone, including enhanced lipid metabolism and improved insulin sensitivity.

Semaglutide is a GLP-1 receptor agonist that mimics native GLP-1 to stimulate insulin secretion in a glucose-dependent manner while suppressing glucagon release. The Aib substitution at position 2 confers resistance to DPP-IV enzymatic degradation, and the C18 fatty diacid chain enables high-affinity albumin binding, extending its half-life substantially. It also acts on hypothalamic appetite centers to reduce food intake and delay gastric emptying.